SML0216
布林佐胺
≥98% (HPLC)
别名:
（R）-4-（乙基氨基）-3,4-二氢-2-（3-甲氧基丙基）-2H-噻吩并[3,2-e] -1,2-噻嗪-6-磺酰胺1,1-二氧化物, AL 4862, （5R）-5-乙基氨基-3-（3-甲氧基丙基）-2,2-二氧代-2?6,9-二硫杂-3-氮杂双环[4.3.0]壬-7,10-二烯-8-磺酰胺
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C12H21N3O5S3
化学文摘社编号:
分子量:
383.51
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥10 mg/mL
storage temp.
−20°C
SMILES string
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
InChI
1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
InChI key
HCRKCZRJWPKOAR-JTQLQIEISA-N
Gene Information
human ... CA2(760)
正在寻找类似产品? 访问 产品对比指南
相关类别
General description
布林佐胺是一种小分子量的化合物，能结合黑色素。该药可用于眼部治疗。
Application
在黑色素结合测定中，布林佐胺已被用作黑色素结合化合物或药物。它也被用作碳酸酐酶抑制剂（CAI）。
Biochem/physiol Actions
布林佐胺是一种用于降低眼压的碳酸酐酶 II 抑制剂。
布林佐胺是碳酸酐酶 II 抑制剂
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Rajendra S Kadam et al.
Drug metabolism and disposition: the biological fate of chemicals, 39(9), 1529-1537 (2011-06-16)
Ophthalmic carbonic anhydrase inhibitors have been shown to improve retinal and optic nerve blood flow. However, the relative tissue distributions of commercially available carbonic anhydrase inhibitors to the optic nerve are not known. The objective of this study was to
Risto S Cvetkovic et al.
Drugs & aging, 20(12), 919-947 (2003-10-21)
Brinzolamide is a highly specific carbonic anhydrase (CA) inhibitor which lowers intraocular pressure (IOP) by reducing the rate of aqueous humour formation. Formulated as a 1% ophthalmic suspension (Azopt) and administered twice or three times daily, brinzolamide is indicated for
James F T Li Yim et al.
Current medical research and opinion, 27(8), 1499-1502 (2011-06-10)
To determine the intraocular pressure (IOP) lowering effect of brinzolamide when added to latanoprost. Patients who were simultaneously on brinzolamide and latanoprost were identified from the large prospective database of patients diagnosed with primary open angle glaucoma, normal tension glaucoma
L DeSantis
Survey of ophthalmology, 44 Suppl 2, S119-S129 (2000-02-09)
The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which
Ivan Goldberg et al.
Journal of glaucoma, 21(1), 55-59 (2010-11-05)
To compare the efficacy of brinzolamide versus placebo when added to travoprost/timolol fixed combination (TTFC) in uncontrolled patients. This was a prospective, double-masked, randomized, placebo-controlled, parallel comparison of ocular hypertensive or primary open-angle glaucoma patients. Patients treated with a prostaglandin-based
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0216-10MG | 04061837077234 |
| SML0216-50MG | 04061832723327 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持